基因融合驱动的皮肤副瘤:一篇更新的评论强调分子特征
Gerardo Cazzato1, Maged Daruish1, Francesco Fortarezza2
1Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", Bari, Italy.
The American Journal of dermatopathology
|February 6, 2025
概括
基因融合是皮肤附带瘤的关键驱动因素. 了解这些分子变化为瘤生物学提供了洞察力,并为晚期皮肤癌提供了潜在的新疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 皮肤病理学 皮肤病理学
背景情况:
- 基因重组和融合越来越多地被认为是皮肤副瘤的关键瘤驱动因素.
- 多种多样的分子变化是这些瘤的病原体的基础.
研究的目的:
- 提供已确定的和新型分子变化的综合性审查,重点关注皮肤附带瘤中的基因融合.
- 突出这些基因变化在瘤生物学中的意义及其治疗影响.
主要方法:
- 关于皮肤附带瘤中基因融合的既定和最新研究的文献综述.
- 对关键分子变化的分析,包括YAP1,CRTC1::MAML2,BRD3,MYB::NFIB,ETV6::NTRK3,PLAG1和更罕见的融合转录.
主要成果:
- 像YAP1,CRTC1::MAML2,MYB::NFIB和ETV6::NTRK3这样的关键基因融合是重要的驱动因素.
- 更罕见的融合,如MEF2C::SS18和FOXK1::GRHL1/2也会导致瘤的发展.
- 这些遗传变化影响瘤生物学,并呈现治疗点.
结论:
- 基因融合在皮肤附带瘤的瘤发生中起着关键作用.
- 了解这些分子驱动因素对于诊断和开发针对高级和转移性疾病的向治疗至关重要.
关键词:
这就是BRD3D3的意思.在CRTC1::MAML2中.ETV6::NTRK3 在线播放MYB::NFIBIB:没有一个.这就是PLAG1的原因.一个YAP1一个YAP1附带性瘤的发生.基因融合 基因融合 基因融合更多相关视频
09:49Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
9.5K
09:58Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
2.7K
相关概念视频
02:23Abnormal Proliferation
4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
02:30Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
02:57Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K